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Abstract
Enhanced signaling by the small guanosine triphosphatase Ras is common in T cell acute
lymphoblastic leukemia/lymphoma (T-ALL, but the underlying mechanisms are unclear. Here, we
identified the guanine nucleotide exchange factor RasGRP1 (Rasgrp1 in mice) as a Ras activator
that contributes to leukemogenesis. We found increased RasGRP1 expression in many pediatric T-
ALL patients, which we did not observe in rare early T cell precursor (ETP) T-ALL patients with
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KRAS and NRAS mutations, such as K-RasG12D. Leukemia screens in wild-type mice, but not in
mice expressing the mutant K-RasG12D that encodes a constitutively active Ras, yielded frequent
retroviral insertions that led to increased Rasgrp1 expression. Rasgrp1 and oncogenic K-RasG12D
promoted T-ALL through distinct mechanisms. In K-RasG12D T-ALLs, we found that enhanced
Ras activation did not lead to cell cycle arrest. In mouse T-ALL cells with increased Rasgrp1
expression, we found that Rasgrp1 contributed to a previously uncharacterized cytokine receptor–
activated Ras pathway that stimulated the proliferation of T-ALL cells in vivo, which was
accompanied by dynamic patterns of activation of effector kinases downstream of Ras in
individual T-ALLs. Reduction of Rasgrp1 abundance reduced cytokine-stimulated Ras signaling
and decreased the proliferation of T-ALL in vivo, suggesting that patients with this cancer should
be screened for increased abundance of RasGRP1 to customize treatment.
Introduction
T cell acute lymphoblastic leukemia/lymphoma (T-ALL) is an aggressive cancer of children
and adults (1). Although dose-intensive therapies have markedly improved the outcomes of
children and adolescents with T-ALL, cure rates for adults with T-ALL remain less than
50%, and the prognosis is poor for patients that relapse at any age (1, 2). Modern genotoxic
treatment regimens also carry a substantial risk of treatment-related toxicity or adverse late
effects (3). Thus, the development of more effective and less toxic therapeutic agents that
are based on the underlying molecular pathogenesis is a high priority. However, T-ALL is a
heterogeneous disease with diverse and complex cytogenetic abnormalities (4-6) and
variable developmental stages (7), which likely will complicate the identification of
universal target molecules. Gene expression microarray studies also point to distinct
developmental stages in T-ALL (8). In contrast to the successful stratification of diffuse
large B cell lymphomas (9), attempts to stratify T-ALL on the basis of developmental
markers have not yet been fruitful (4, 10-12).
Enhanced signaling by the small guanosine triphosphatase (GTPase) Ras is implicated in the
pathogenesis of ∼50% of T-ALL cases (13), but the molecular mechanisms causing aberrant
Ras signaling in T-ALL are not well understood. Ras is normally activated by guanosine
triphosphate (GTP)-loading by Ras guanine nucleotide exchange factors (RasGEFs), which
include Son of Sevenless (SOS), Ras guanine nucleotide–releasing protein (RasGRP), and
Ras guanine nucleotide–releasing factor (RasGRF) (14). The intrinsic, deactivating, GTPase
activity of Ras is strongly enhanced by critical inhibitors of Ras, the Ras GTPase-activating
proteins (RasGAPs) (15). Somatic mutations in the gene encoding Ras that result in an
accumulation of the GTP-bound form of the Ras protein are among the most frequent
oncogenic lesions in metastasizing disease (16). Biochemically, these mutations, such as K-
RasG12D, lead to a severely impaired GTPase activity of Ras (17) that is no longer enhanced
by RasGAPs. For unknown reasons, somatic NRAS and KRAS mutations are relatively rare
in T-ALL (18-20), accounting for only ∼10% of T-ALL cases, which leaves a large
proportion of the T-ALL cases with enhanced Ras activation (13) that are unexplained.
Three studies have uncovered important insights regarding the role of Ras and cytokine
signaling in T-ALL. Whole-genome sequencing revealed that NRAS and KRAS mutations,
as well as activating mutations in Janus activating kinase 1(JAK1) and JAK3 or activating
mutations in the IL7R [which encodes the interleukin-7 receptor (IL-7R)], occur with much
higher frequency in a specific subtype of T-ALL, early T cell precursor (ETP) T-ALL,
which is typically associated with a poor clinical outcome (21). Biochemically, these T-ALL
IL-7R mutations result in constitutive activation of the kinase JAK1 downstream of the
receptor independently of IL-7 binding, which results in cellular transformation and tumor
formation (22). The connection between IL-7 and TALL was further substantiated in a third
study that showed that the proliferation of xenografted patient leukemias in the bone marrow
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and leukemia-associated morbidity are diminished in a mouse model that is deficient in IL-7
(23).
In contrast to ETP T-ALL (21), somatic RAS mutations are relatively rare in most T-ALL
(18-20); however, Ras signaling is aberrantly high in 50% of cases (13). With analyses of
pediatric T-ALL patient samples, investigation of common integration sites (CIS) in mouse
leukemia virus screens, and biochemical assays aided by in silico methods, we found that
Rasgrp1 is a frequently affected RasGEF in T-ALL. We found that increased Rasgrp1
protein abundance contributed to Ras activation in T-ALL in a manner that was
biochemically distinct from that induced by oncogenic K-RasG12D mutations. Increased
Rasgrp1 abundance alone resulted in only weak, basal Ras signaling that did not trigger cell
cycle arrest. Instead, we found that increased Rasgrp1 abundance cooperated with cytokine
receptor signaling to activate Ras and stimulate leukemogenesis. Lastly, we observed a high
degree of heterogeneity in the activation of kinase pathways downstream of Ras, as well as
evidence for plasticity in pro-survival signaling pathways in response to perturbations in
Rasgrp1. We discuss how our data contrasting enhanced Rasgrp1 abundance with oncogenic
K-RasG12D mutations provide new hypotheses and potential targets that can be exploited in
the future to better understand how to intervene with different types of T-ALL Ras signaling
with molecularly targeted therapeutic agents.
Results
Increased RasGRP1 expression in T-ALL patients and its predicted effect on Ras
Through computational analyses and cellular assays, we previously demonstrated that the
RasGEF Rasgrp1 is necessary and sufficient to trigger Ras activation in lymphocytes, in
contrast to Sos1, a Ras activator that functions best when Rasgrp1 is also present (24). To
better understand how enhanced Ras signaling occurs in 50% of T-ALL cases, we used
computational methods to simulate the activity of Rasgrp1. Given the identification of
NRAS and KRAS mutations in ETP T-ALL (21), which occur with only low frequency in
other T-ALLs (18-20), we explored what other biochemical events could in principle explain
the enhanced Ras signaling in ∼50% of T-ALL cases (13). We used our established
computational models (fig. S1A) that stochastically simulate the Ras activation-deactivation
cycle through Rasgrp, SOS, and RasGAP (24). To mimic NRAS or KRAS mutations that
impair the GTPase activity of Ras (17), we decreased either the catalytic rate or the
concentration of RasGAP in our model. As expected from the established inhibitory function
of RasGAPs in the Ras activation-deactivation cycle (15), both impairments in RasGAP
(catalytic activity and concentration) were predicted to lead to increases in the steady-state
abundance of RasGTP at low, basal amoiunts of SOS (Fig. 1, A and B). These predictions
remained the same when the constant amount of SOS activity was increased (fig. S1, B and
C). Our simulations also predicted that decreases in the catalytic rate or concentration of
RasGAP would increase the abundance of RasGTP (Fig. 1A and fig. S1).
Next, we performed several perturbations of Rasgrp and SOS, and we noted that increases in
the catalytic rate of Rasgrp also predicted substantial correlative increases in RasGTP
abundance (Fig. 1A). In contrast, when we merely increased the number of Rasgrp
molecules in the simulation did not increase the abundance of RasGTP accordingly,
indicating that there was a parameter in addition to the Rasgrp concentration that was rate-
limiting (Fig. 1B). As before (24), we used our computational models to formulate new
hypotheses in this study, focusing on predictions of major characteristics. However, we did
not concentrate on fitting the models to the biological data in terms of specific amplitude
and timing of responses or specific concentrations of signaling molecules.
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Increased RasGRP1 mRNA abundance has been reported in microarray studies of primary
human T-ALLs and cell lines (19, 25, 26). In contrast, RasGRP1 expression is decreased in
the ETP T-ALL subtype (21). We found that established human T-ALL lines exhibited a
range of RasGRP1 protein abundance, showing up to a 10-fold increase compared to that in
normal human T lymphocytes (Fig. 1C). These T-ALL lines represent a range of
developmental stages, based on their cell-surface markers (27). When we examined primary
patient samples, we confirmed the published microarray studies with real-time reverse
transcription polymerase chain reaction (RT-PCR) analysis of 11 pediatric T-ALL patients.
Six patients had increased RasGRP1 mRNA abundance, whereas five patients had RasGRP1
mRNA abundance that was similar to those of normal bone marrow donors (Fig. 1D). A
similar small-scale survey also identified high RasGRP1 expression in 3 out of 6 T-ALL
patients (28).
We subsequently investigated the expression patterns of all eight RasGEFs through the
analysis of microarray data from 107 pediatric patients that were enrolled in Children's
Oncology Group studies 9900/9404 and AALL03B1/AALL0434. We observed a 128fold
range in RasGRP1 expression (from 24 to 211 in normalized array intensities, Fig. 1E). This
extensive expression range was unique to RasGRP1 and was not seen for the genes encoding
the other 7 RasGEFs (Fig. 1F). Graphing the extent of RasGRP1 expression as a function of
clinical outcome revealed an inverse correlation. With an arbitrary cut-off, 7 of 14 (50%) of
patients that had low RasGRP1 expression failed to achieve a first remission [induction
failure (IF)] with treatment in the two clinical trials (Fig. 1G), whereas most of the patients
with high RasGRP1 expression (88 of 93, or 95%) went into remission followed by a relapse
(RE) or into complete continuous remission (CCR).
Rasgrp1 integrations are highly prevalent in mouse T-ALLs generated by retroviral
insertional mutagenesis
We next examined two independent mouse leukemia screens and identified Rasgrp1 as a
common integration site (CIS). In the first retroviral insertion mutagenesis (RIM) screen, T
lineage leukemias were induced by SL3-3 mouse leukemia virus insertions in Balb/C mice.
Fathers of SL3-3–infected mice were treated with the ENU mutagen (29) to generated
random mutations in the genome before being infected with leukemia virus. In 237
leukemias, CIS were found within ∼159 kb of Rasgrp1, a frequency similar to that of the
leukemia-associated oncogenes Evi5, Notch1, and pvt1 (Fig. 2A). As an example, Notch1
expression becomes activated by both retroviral CIS and point mutations in mouse T-ALL
(30), and Notch1 is a very common target of somatic mutation in human T-ALL (31). In
contrast to the abundant SL3-3 CIS in Rasgrp1, we found only one insertion each in Rasgrp4
and Rasgrf1, but none in the genes encoding the other five RasGEFs from a total of 6234
mapped integrations (Fig. 2B). Despite our predicted effects of reduced RasGAP activity or
abundance on Ras activation (Fig. 1), we observed very few insertions in genes encoding
RasGAPs (Fig. 2C). Consistent with this finding, inactivation of the RasGAP-encoding NF1
occurs infrequently in pediatric T-ALL (32), although these results may reflect the lower
statistical chance of interrupting the coding region of the genes of inhibitors such as
RasGAP proteins. Most of the Rasgrp1 insertions mapped to the promoter region, some to
intron 1, and one single SL3-3 tag marked the 3′-untranslated region (UTR) (Fig. 2D, and
figs. S2, A and B, and fig, S3).
CIS in Rasgrp1 have been reported in other RIM screens of smaller-scale (see fig. S2B for
CIS positions) (33-35). Transgenic over-expression of Rasgrp1 causes thymic lymphomas in
mice (36), and retroviral overexpression of Rasgrp1 in bone marrow cells followed by
transplantation into sublethally irradiated recipient mice results in T-ALL with
CD3lowCD4+CD8+Thy1+ leukemic T cells (28), but the mechanisms by which Rasgrp1
contributes to leukemogenesis have not been explored. In normal thymocytes, Rasgrp1
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mRNA amounts are dynamic during development (37) and are reduced in response to T cell
receptor (TCR) stimulation (38). To investigate the effect of CIS in Rasgrp1, we first
generated clonal T-ALL cell lines from primary leukemia tumors and subsequently derived
daughter cell lines in which we targeted RasGRP1 or SOS1 expression with lentiviruses
expressing specific short hairpin RNAs (shRNAs). This panel of cells also included two T-
ALL cell lines, numbers 55 and 98, that had SL3-3 integrations in loci other than Rasgrp1,
and displayed similar amounts of the TCR, CD4, and CD8 developmental markers to those
of T-ALL cell lines with Rasgrp1 insertions (Fig. 2E and fig. S3, B and C). The SL3-3
Rasgrp1 CIS T-ALL cell lines demonstrated increased amounts of Rasgrp1 mRNA in
comparison to those of the SL3-3 T-ALL 98 cell line (Fig. 2E and fig. S3C). Together, these
data demonstrate that retroviral CIS in Rasgrp1 are uniquely frequent and result in
dysregulated, enhanced Rasgrp1 expression in mouse T-ALL.
Dysregulated Rasgrp1 and K-RasG12D are mutually exclusive and cause distinct Ras
activation as well as in vitro and in vivo proliferative patterns
We also observed Rasgrp1 CIS in 3 of 6 T-ALLs in a second, smaller screen with MOL4070
retrovirus in wild-type C57BL/6/129SvJ mice, and we generated the C6 and C7 MOL4070
T-ALL cell lines. In contrast, 46 T-ALL from the same MOL4070 RIM screen performed in
mice with a genetic K-RasG12D mutation (39) did not harbor any Rasgrp1 CIS, suggesting
that oncogenic K-RasG12D mutations and insertions in Rasgrp1 do not have additive effects
in leukemogenesis.
Similar to the regulation of its mRNA, Rasgrp1 protein abundance is also regulated in a
dynamic manner and decreases after the maturation of normal developing T cells (40, 41). In
agreement with the effects of CIS in Rasgrp1 on its mRNA abundance, Rasgrp1 protein
amounts were ∼4- to 6-fold greater in all murine T-ALL with Rasgrp1 CIS than in normal
total thymocytes and lymph node T cells (Fig. 3A and fig. S3D), differences that are similar
in magnitude to what we observed for human T-ALL lines (Fig. 1C). In contrast, Rasgrp1
protein was low in abundance in the T-ALL 55 and 98 cell lines, which had similar amounts
of the markers TCR, CD4, and CD8, but had other CIS, not in Rasgrp1 (fig. S3D). Rasgrp1
protein was practically undetectable in all six K-RasG12D TALL lines (Fig. 3A and fig.
S3D). Five of these six K-RasG12D T-ALL lines had undetectable cell-surface TCR,
indicative of these cell being at an earlier developmental stage than those of the other cell
lines examined. This mirrors the human disease with RAS mutations and the early
developmental stage of ETP T-ALL (21). It is possible that Rasgrp1 protein is undetectable
in ETP T-ALL types (21) because normally early thymocyte subsets express low amounts of
Rasgrp1 (40, 41). Thus, our panel of murine T-ALL lines spans different developmental
stages, similar to what has been reported for human T-ALL lines (27) and in agreement with
the apparent variation in the developmental stages of primary T-ALL in patients (4, 7, 8,
10-12).
Our panel of cell lines from SL3-3–induced leukemias with Rasgrp1 integrations and cell
lines from MOL4070-induced K-RasG12D mutant and wild-type leukemias enabled us to
directly compare the biochemical effects of dysregulated Rasgrp1 and oncogenic K-RasG12D
expression on Ras, as well as explore potential differences in the underlying molecular
mechanisms of the associated T lineage leukemogenesis. We first examined the amounts of
RasGTP in these clonal T-ALL lines under basal, serum-free conditions. As anticipated
from their impaired GTPase function (17), all K-RasG12D T-ALL cell lines had increased
amounts of GTP-loaded Ras in the basal state compared to that of Rasgrp1 T-ALL cell lines
(Fig. 3A). In contrast, Rasgrp1 T-ALL lines displayed only low amounts of RasGTP under
basal conditions, which were further reduced in a T-ALL daughter line in which Rasgrp1
abundance was reduced by 57% by Rasgrp1-specific shRNA (fig. S3E).
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Paradoxically, strong oncogenic signals can trigger cell cycle arrest and promote apoptosis,
and the p53-p21 CDK-interacting protein (p21CIP) arrest pathway plays a central role in this
response (42, 43). This pathway can be induced by robust signals from Myc or Ras
oncogenes and by DNA damage, and it is often disrupted in cancer (42, 43). Based on the
different extents of basal Ras signaling in our T-ALLs, we hypothesized that K-RasG12D and
Rasgrp1 T-ALL might show distinct patterns of cell cycle arrest. Indeed, the
phosphorylation of p53 and the production of the p53 target p21CIP were constitutively
induced in the K-RasG12D T-ALL cell lines 6, 3, and 51 (Fig. 3B). In a second group of K-
RasG12D T-ALL cell lines (which included lines 9, 15, and 7), we did not observe triggering
of the expected p53-p21CIP arrest pathway. In contrast, the abundances of phosphorylated
p53 (pp53) and of p21CIP were very modest in all Rasgrp1 T-ALL lines that had low
amounts of RasGTP under basal conditions (Fig. 3B and fig. S4). As a positive control, we
showed that the p53-p21CIP pathway was stimulated by doxorubicin-induced DNA damage
in T-ALLs (fig. S4, A and B).
These distinct biochemical features were reflected in different cellular proliferative patterns
in vitro. The K-RasG12D T-ALL cell lines 6, 3, and 51 underwent apoptosis and cell death in
the absence of exogenous growth factors, as measured by staining with Annexin V- or with
Annexin V and propidium iodide (PI) (fig. S4C). These same cell lines showed modest
proliferation in vitro that depended on the presence of IL-2, IL-7, and IL-9 in the culture
medium (Fig. 3C and fig. S5). The K-RasG12D T-ALL cell lines 9, 15, and 7 and all of the
Rasgrp1 T-ALL lines showed little apoptosis and cell death (fig. S4, D and E), which
resulted in exponential cellular proliferation in vitro even in the absence of cytokines or
when the amount of fetal calf serum in the medium was reduced (Fig. 3C and fig. S5).
To investigate the basal proliferative potential of these cell lines in vivo, we transplanted
nude mice subcutaneously with T-ALLs because this region of the mouse represents a non-
hematopoietic site that typically lacks abundant growth factors. Nude mice are also
immunocompromised, which enabled us to make a direct side-by-side comparison of TALL
lines derived from mice with different genetic backgrounds (Balb/C and C57BL/6/129). In
agreement with our earlier in vitro data, we found that mice injected with the K-RasG12D T-
ALL 3 and 6 cell lines never developed tumors subcutaneously, whereas all 8 mice that
received the K-RasG12D T-ALL 9 or 15 cell lines developed palpable tumors after 12 to 14
days (Fig. 3D and fig. S6). Eight of the 10 mice that were injected with two independent
Rasgrp1 T-ALL cell lines (1156S-O and 1713S-N) also developed tumors (Fig. 3D and fig.
S6). We reduced the abundance of Rasgrp1 in 1156S-O cells by 57% (by infecting them
with retrovirus expressing Rasgrp1-specific shRNA and found that this decreased the
incidence of tumors in transplanted mice compared to mice transplanted with 1156S-0 cells
expressing GFP (Fig. 3D and fig. S6). Thus, increased Rasgrp1 abundance contributed to T-
ALL cell proliferation and tumor development in vivo. We did not observe the anti-
proliferative effects of Rasgrp1-specific shRNA in T-ALLs in vitro at the 96-hour time point
(fig. S5), which indicated that the in vivo assays were more stringent tests of growth
potential.
Reduced Rasgrp1 abundance retards T-ALL development in hematopoietic organs
Cytokines play an important role in leukemogenesis and leukemia progression, and
transgenic overexpression of IL-7 or IL-9 promotes these processes in mouse models (44,
45). These studies were further substantiated by the identification of activating mutations in
the gene encoding IL-7R in T-ALL patients (21, 22). Cytokine receptors of the common γ
chain (γc) family relay signals through the common γ chain to promote the proliferation
and survival of T-ALLs in response to stimulation by their cytokines (46, 47). Part of this
cytokine receptor response occurs through the JAK-signal transducer and activation of
transcription (STAT) axis (48), which can be involved in T-ALL patients (49), although
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other pathways could also play a role. To first test if our T-ALL cell lines were subject to
autocrine cytokine stimulation, we examined the expression of IL2, IL7, and IL9 in our
clonal lines that were grown in log phase in tissue culture. The K-RasG12D T-ALL 3 and 6
cell lines, which had impaired proliferation (Fig. 3), had relatively large amounts of IL2 and
IL7 mRNAs and small amounts of IL9 mRNA, as measured by realtime RT-PCR analysis,
with the amounts of IL9 mRNA slightly increased compared to those of activated CD4+ T
cells (Fig. 4, A and B). In contrast, the amounts of these cytokine mRNAs were negligible in
all other T-ALL lines (Fig. 4A) in vitro and after being transplanted subcutaneously into
mice, and were not affected by knockdown of Rasgrp1 (Fig. 4C), indicating that autocrine
stimulation of cells with IL-2, IL-7, or IL-9 did not play a substantial role in the autocrine
stimulation of our T-ALL lines.
We reasoned that cell proliferation could be stimulated by cytokines produced by stromal
cells. To test this hypothesis, we injected Rasgrp1 T-ALL lines into the mouse circulatory
system. Similar to what is observed in T-ALL patients, Rasgrp1 T-ALL cell lines
preferentially proliferated in the hematopoietic organs of injected mice. Two weeks after the
introduction of 4000 cells into recipient mice, we observed large percentages of green
fluorescent protein (GFP)-marked 1156S-O and 3397S-E T-ALL cell lines in the bone
marrow and livers (Fig. 4D and fig. S7B). Knocking down Rasgrp1 in 1156S-O TALL cells
by 57% with shRNA before being injected into mice (Fig. 5B) significantly reduced the
frequency of GFP+ cells in the bone marrow and liver compared to that of control mice
injected with cells in which Rasgrp1 had not been knocked down (Fig. 4D, P = 0.011 and
0.007, respectively). Knockdown of Rasgrp1 by 37% in 3397S-E T-ALL cells resulted in a
similar trend in the bone marrow, although auto-fluorescence interfered with the lower
amounts of GFP in this T-ALL line, particularly hindering the analysis in the liver (fig. S7,
A and B). Knockdown of Rasgrp1 was relatively stable in vivo and extended the mean
survival times of mice transplanted with 1156S-O T-ALL cells (fig. S7, C and D).
Histological examination of blood smears indicated an increased proportion of circulating
blasts in the peripheral blood of mice injected with 1156S-O T-ALL cells compared to that
of mice injected with 1156S-O cells in which Rasgrp1 was knocked down by shRNA (Fig.
4E). Similarly, H&E- and Rasgrp1-staining indicated a high T-ALL burden in the bone
marrow and livers of these mice. Morphologically homogeneous T-ALL blasts that were
positive for Rasgrp1 in the bone marrow resulted in concomitant loss of cellular
heterogeneity in the bone marrow (for example, notice the decrease in megakaryocytes).
Similarly, T-ALL cells also efficiently proliferated in the liver and caused destruction of the
normal hepatocyte network (Fig. 4F). This pathology was substantially reduced when
Rasgrp1 was knocked down in the injected cells (Fig. 4F). These results demonstrate that
reducing Rasgrp1 abundance, even only partially, retards tumor growth in vivo, suggesting
that Rasgrp1 might be an attractive target molecule for future cancer therapy.
Increased Rasgrp1 abundance increases the responsiveness of cells to diacylglycerol
stimulation
Basal amounts of RasGTP are only modestly increased in Rasgrp1 T-ALL cell lines;
however, all of these cell lines exhibit substantial proliferative responses in vitro. In normal
lymphocytes, the membrane-recruitment and activation of Rasgrp1 depends on
diacylglycerol (DAG), a second messenger that is produced by phospholipase Cγ (PLC-γ)
(50). To test whether Rasgrp1 T-ALL lines were responsive to DAG, we stimulated them
with phorbol myristate acetate (PMA), a synthetic version of DAG, and monitored the
activation of Ras. PMA most stimulated the production of RasGTP when Rasgrp1
abundance was high. Induction of RasGTP was more modest in a control T-ALL 55 cell line
without CIS in Ras-related genes coming from the same SL3-3 screen, and RasGTP was
also reduced in T-ALL lines expressing Rasgrp1-specific shRNA (Fig. 5, A to C). The
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amount of Rasgrp1 in all of the T-ALL cell lines also directly correlated with the extent of
phosphorylation (and activation) of the mitogen-activated protein kinase (MAPK)
extracellular signal–regulated kinase (ERK), which is downstream of the RasGTP-Raf
kinase-MEK [mitogen-activated or extracellular signal–regulated protein kinase kinase
(MAPKK)] pathway (fig. S8, A to G).
Because DAG amounts and turnover play a role in controlling Rasgrp-induced Ras
activation in normal lymphocytes (51), we used our computational model (Fig. 1) to explore
the effects of incrementally increasing the amounts of Rasgrp and DAG in TALL. Jointly
varying the concentrations of both components, while keeping SOS at a fixed amount of 5 or
15, predicted a strong cooperation between the increased amounts of Rasgrp and of the
second messenger DAG in the simulations (Fig 5, D and E). Note that both concentrations of
SOS resulted in sigmoid curves for RasGTP abundances as a function of DAG and Rasgrp
concentrations, predicting that there is a threshold phenomenon for DAG-Rasgrp-Ras
signaling in T-ALL. These simulations led us to suggest the hypothesis that sufficient
amounts of basal DAG or of newly generated DAG in response to upstream receptor signals
might be required for the effect of increased Rasgrp1 abundance in T-ALL.
The amount of Rasgrp1, but not Sos1, determines the strength of the cytokine-Ras
response
In normal lymphocytes, RasGRP1 and SOS1 are recruited to the plasma membrane and
cooperate to activate Ras when the TCR or B cell receptor (BCR) is stimulated; however,
RasGRP1 is dominant over Sos1 (52). The dominant effect of RasGRP1 can be explained by
the fact that the RasGRP1-generated RasGTP not only transmits signals to its downstream
effectors, such as the kinase Raf, but also exponentially enhances the GEF activity of SOS
by binding to SOS and allosterically activating SOS so that much more RasGTP is produced
(24, 52, 53). Thus, the allosteric activation of SOS is facilitated by RasGRP1. To predict
how receptor signals might influence Ras activation in our T-ALL, we incorporated receptor
input into our computational models, following Riese et al. (51), and determined RasGTP
abundance as a function of increasing concentrations of Rasgrp and increasing receptor
signal input at simulation time units of t = 5 and 15 (Fig. 6, A and B). The resultant sigmoid
curves indicated that once Rasgrp concentrations surpass a certain threshold, in these
particular cases for arbitrary amounts of Rasgrp greater than ∼100 simulation concentration
units, RasGTP is generated very efficiently in the context of receptor stimulation. Moreover,
and conversely, it was predicted that when the amount of Rasgrp drops below this threshold
(for example, when Rasgrp = 50 or 75 units, Fig. 6, A and B), RasGTP generation will be
very limited, even when signal input is substantial.
To test these predictions and to mimic the exposure of T-ALL to physiological stimuli such
as growth factors produced by stromal cells, we stimulated our cell lines with a cocktail of
the cytokines IL-2, IL-7, and IL-9. Such stimulation resulted in strong RasGTP production
in Rasgrp1 T-ALL (Fig. 6, C to E). The shRNA-dependent knockdown of Rasgrp1 by 55
and 48% in 1156S-O and T-ALL C6 cells, respectively, resulted in markedly reduced
cytokine-induced amounts of RasGTP compared to those in control cells (Fig. 6, D and E),
suggesting that Rasgrp1 responds to a cytokine receptor– induced signaling pathway. Note
that these cytokine-induced Rasgrp1-RasGTP responses were transient and that the amounts
of RasGTP generated were lower than the basal amounts of RasGTP in the K-RasG12D T-
ALL-3 line. In addition, a combination of IL-2, IL-7, and IL-9 enhanced the already
increased amount of RasGTP in the K-RasG12D TALL 3 cell line (Fig. 6C).
Sos1 is found in our T-ALL lines (Fig. 6, C to E) and is presumably recruited to stimulated
cytokine receptors through the adaptor molecules Shc and Grb2, which link the receptors to
SOS, so it can activate membrane-bound Ras (54). Our previous work suggested that Rasgrp
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transduces essential low-level receptor signals to Ras in an analog manner until a threshold
of receptor input is reached, at which point the character of the Ras activation is altered
because SOS is also engaged, which results in digital Ras signals or a sharp threshold that
separates weaker signaling from strong signaling (24, 55). This does not mean that Rasgrp
alone cannot generate strong Ras signals. For example, here we predicted (Fig. 1) that for T-
ALL, complete removal of SOS (SOS = 0) still enabled the generation of substantial
amounts of RasGTP, provided that the simulation concentration units of Rasgrp1 were
sufficiently high (> ∼100). However, the exponential pattern of RasGTP generation was
predicted to be absent without SOS (Fig. 6F), which is consistent with our past experimental
results (24, 55). We tested the efficacy of various Sos1-targeting shRNA constructs.
Unfortunately, none of these resulted in a complete knockdown of Sos1, and therefore the
effect of the predicted loss of exponential Ras activation (Fig. 6F) is likely best tested
through genetic Sos1-deleting models that will have to be generated in the future. However,
reduction of Sos1 abundance by 42%, which was similar in magnitude to the knockdown of
Rasgrp1observed earlier (Fig. 6, D and E), did not affect the strength of cytokine-induced
Ras activation in the T-ALL C6 cell line (Fig. 6G). Thus, cytokine-induced Ras activation in
Rasgrp1 T-ALL is more sensitive to decreases in Rasgrp1 abundance than to decreases in
Sos1 abundance.
Gene expression profiling and cell-surface marker profiling have not yet led to a successful
stratification of T-ALL (4, 7, 8, 10-12), which contrasts with the successful classification of
diffuse large B cell lymphoma (9). Here, we made a start to explore the biochemical
stratification of T-ALL. The heterogeneity in cytogenetic abnormalities (4-6) and the
differences in developmental stages of T-ALL (7) are likely to increase the biochemical
diversity and may complicate the identification of a universal molecular target for clinical
intervention. Indeed, the limited cell proliferation assays that have been reported with T-
ALL patient cells demonstrate a wide range of responses to stimulation with various
cytokines in vitro (47), suggesting a high degree of heterogeneity in the signals transmitted
through the cytokine receptor pathways.
RasGTP signals to multiple effector kinase pathways, such as the Raf-MEK-ERK and the
phosphoinositide 3-kinase (PI3K)–Akt–mammalian target of rapamycin (TOR)-S6 kinase
pathways that stimulate cell proliferation and survival (54, 56). Directly targeting oncogenic
Ras proteins is difficult, because it would involve restoring the impaired GTPase function of
Ras, and has not proven feasible to date (57). As a result, considerable effort is ongoing to
interfere with molecules downstream of Ras in clinical settings, such as MEK or PI3Ks (56),
as potential cancer therapies. Consistent with the reported heterogeneous proliferative
responses (47), we observed heterogeneous patterns of phosphorylation of ERK and Akt in
our panel of human T-ALL cell lines that did not correlate with RasGRP1 abundance (Fig.
6H). Variability in activity through the PI3K-Akt pathway in some of these T-ALL lines was
previously noted (26, 58). Similarly, our murine T-ALL lines that proliferated after
subcutaneous injection in vivo also exhibited heterogeneous activation of these effector
kinase pathways. Analysis of cells from two tumors removed from mice independently
injected with the K-RasG12D T-ALL 15 cell line demonstrated that they exhibited Akt
signaling, whereas cells from two T-ALL 9–derived tumors with the same genetic K-
RasG12D lesion did not (Fig. 6I). Because cells from all eight tumors derived from the K-
RasG12D T-ALL 15 and 9 cell lines proliferated to similar extents (fig. S6), we conclude that
the T-ALL 9 cells must have other signals engaged that have a biological function similar to
that of Akt signaling in T-ALL 15 cells. Moreover, we found that clonal 1156S-O Rasgrp1
T-ALL that independently proliferated in vivo used the pro-survival nuclear factor κB (NF-
κB) pathway (59), as determined by detection of the phosphorylation of the NF-κB inhibitor
protein IκBα (Fig. 6I). In two transplants with cells expressing Rasgrp1-specific shRNA,
NF-κB signaling appeared to be replaced by Akt signaling (Fig. 6I), which also promotes
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cell survival (54, 56). The PI3K-Akt pathway, which includes inhibitor signaling by
phosphatase and tensin homolog deleted from chromosome 10 (PTEN), is implicated in
∼50% of T-ALL patients (60). Furthermore, the TANK-binding kinase 1 (TKB1)–NF-κB
pathway can play a critical role in various human cancers with oncogenic Ras mutations (61,
62); however, currently we do not have further evidence to substantiate a Rasgrp1–NF-κB
pathway, nor do we have a molecular understanding of the how cells switch from using NF-
κB signaling to Akt signaling to survive. Thus, our panel of clonal mouse T-ALL lines not
only retained a complex level of heterogeneity but also plasticity in terms of Ras effector
activation. We postulate that this panel of cell lines may serve as a useful tool for future
studies to further explore the heterogeneity and plasticity characteristics of Ras effector
kinase pathways in patients.
Discussion
We found that RasGRP1 expression is increased in many T-ALL patients as well as in
mouse T-ALLs that were caused by leukemia virus–dependent insertions in Rasgrp1. In
contrast, RasGRP1 expression is low in ETP T-ALL patients (21), and we observed no
Rasgrp1 CIS on a K-RasG12D mouse genetic background. We demonstrated that increased
Rasgrp1 abundance resulted in only modest basal Ras activation, which did not trigger cell
cycle arrest responses. Instead, our computational, biochemical, and mouse model
approaches demonstrated that Rasgrp1 effectively responds to cytokine receptor input to
activate Ras in T-ALL, revealing a previously uncharacterized cytokine receptor– Rasgrp1
pathway. The kinase effector pathways downstream of Ras are not “locked-in” but are
highly heterogeneous in both human and murine T-ALL lines, and biochemical “rewiring”
occurred in a plastic manner after perturbation of the signaling network. Reduction of
Rasgrp1 retarded tumor growth, which suggests that Rasgrp1 might be an attractive target
for therapies against T-ALL.
At this point, we do not know what causes the increased RasGRP1 mRNA abundance in
human T-ALL. RasGRP3 is also found in the T cell lineage, and RasGRP4 was originally
isolated from acute myeloid leukemia (AML) patient cDNA (63), but our microarray
platform with 107 T-ALL patients and the large RIM screens for T-ALL found changes only
in Rasgrp1 among the RasGRPs tested (Fig. 2). We are currently investigating the
underlying mechanism for the specificity regarding Rasgrp1. The absolute amount of
Rasgrp1 protein is relatively modest in human T-ALL lines and our murine T-ALL, even in
those with the greatest amounts of Rasgrp1 mRNA. We hypothesize that it is the
dysregulation of expression rather than the absolute increase in Rasgrp1 protein abundance
that contributes to leukemogenesis. In support of the regulation of expression as an
important mechanism to curb Rasgrp1 function, Rasgrp1 mRNA amounts are dynamic in
thymocyte subsets (37) and are reduced in response to TCR stimulation (38), and Rasgrp1
protein abundance decreases when thymocytes mature to T cells (40, 41). Indeed, even a
partial reduction in Rasgrp1 abundance had a substantial effect on cytokine-induced Ras
activation and proliferation of cells in vivo, suggesting that Rasgrp1 may be an attractive
molecule to inhibit to interfere with cellular proliferation.
Based on the combined published microarray data (19, 25) and our data here, we postulate
that dysregulation of RasGRP1 is a common feature of human T-ALL and that it is more
frequent than are oncogenic mutations in RAS. It is possible that signals from oncogenic Ras
mutations are too strong for cells in the T lymphocyte lineage. We observed that in half of
our mouse K-RasG12D T-ALL lines, the intrinsic Ras signal was uncoupled from the p53-
p21 response. Deletion of the p53-regulators encoded by the INK4A/ARF locus occurs very
frequently in T-ALL patients (4). Still, somatic mutations in N-RAS and K-RAS do not
occur with high frequency (18-20), and perhaps dysregulation of p53 alone is not sufficient
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for K-RasG12D T-ALL to develop in patients. In support of this notion, patients with ETP T-
ALL that are now known to often carry strong activating alleles, such as oncogenic K-RAS
or N-RAS mutations or activating mutations in IL7R, demonstrate a very high burden of
additional cytogenetic abnormalities (21). Perhaps a specific set of genetic abnormalities
enables the ETP TALL cells to proliferate despite having strong oncogenic signals that can
trigger cell cycle arrest. ETP T-ALL is an aggressive malignancy that is often associated
with treatment failure (64), and ETP T-ALL patients have low expression of RasGRP1(21).
We found a strong correlation between low RasGRP1 expression and failure to respond to
treatment in two COG clinical trials with 107 pediatric T-ALL patients. Lack of available
DNA prevented us from directly testing this, but it is tempting to speculate that the 7 T-ALL
patients that failed treatment and had very low RasGRP1 expression instead had mutations
in KRAS or NRAS and may represent cases of ETP T-ALL. Future studies need to focus on
this aspect, particularly because RasGRP1 may provide a means of stratifying patients,
ideally before treatment begins.
Rasgrp1-deficient mice show a selective defect in T lymphocyte development (65), and
Rasgrp1 and Rasgrp3 have predominantly been studied as RasGEFs that operate
downstream of the TCR and BCR (50). Reports combined with our finding of a cytokine
receptor–Rasgrp1-Ras pathway indicate that RasGEFs of the Rasgrp family also operate
downstream of receptors other than the TCR and BCR. We therefore hypothesize that the
concept of dysregulated RasGRP1 responding to receptor input may be more general and
applicable to different types of cancer. There is some evidence for this hypothesis. For
example, in a Keratin5-RasGRP1 transgenic mouse model, RasGRP1 overexpression results
mostly in skin papilloma but synergizes with 12-O-tetradecanoylphorbol-13-acetate (TPA)
treatment to stimulate the tumorigenic response (66). TPA is a phorbol ester that activates
RasGRP1 as well as other molecules. RasGRP3 is found in a subset of human prostate and
melanoma cancer samples, and RasGRP3-specific shRNA reduced hepatocyte growth factor
(HGF)- or epidermal growth factor (EGF)-induced Ras signaling in prostate or melanoma
cancer cell lines, as well as reduced xenograft tumor formation (67, 68). Although a
biochemical connection between the activation and membrane-recruitment of the RasGRPs
and the HGF, EGF, and cytokine receptors has not been firmly established, a role for DAG
is possible. This might lead to new opportunities to interfere with oncogenic Rasgrp signals
through the use of inhibitors of the PLC enzymes that produce DAG. Here, we focused on
the role of Rasgrp1 downstream of the receptors for IL-2, IL-7, and IL-9 in the activation of
Ras. We would like to emphasize that it is very plausible that Rasgrp1 responds to signaling
by other receptors in T-ALL or that it may activate pathways other than Ras that are
aberrantly triggered by increased, dysregulated Rasgrp1. These possibilities, and the
question of whether DAG is a prerequisite for dysregulated Rasgrp1 to be leukemogenic, are
important topics for future investigations. Regardless, our results indicate that Rasgrp1 itself
could be a very attractive target in cancer therapy, especially because (i) our models predict
that inhibition of Rasgrp1 activity below a threshold will have profound effects on Ras
activation, and (ii) partial knockdown of Rasgrp1 has a noticeable effect on the proliferation
of T-ALL cells.
Understanding the complexity of the Ras signaling network in T-ALL and cancer in general
will be essential to guide future clinical intervention with small molecules that inhibit
specific components in effector pathways downstream of Ras. We report considerable
heterogeneity and plasticity in receptor-induced Ras effector pathways in either Rasgrp1 or
K-RasG12D T-ALL. Plausible sources of heterogeneity are different combinations of CIS,
acquired or induced (ENU) mutations, and the diverse developmental stages found for T-
ALL. Here, we focused mostly on the biochemical mechanism of the role of RasGRP1 in T-
ALL and we did not address the particular developmental stage(s) that Rasgrp1 might affect.
Elegant application of the Sleeping Beauty system in distinct developmental subsets
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indicated that insertions in Rasgrp1 leading to T-ALL typically occur in early hematopoietic
subsets and often also acquire insertions in Notch1(69). These studies also initiated the
interesting discussion that ETP T-ALL perhaps arise from a later developmental stage but
differentiate backwards (69, 70).
A substantial portion (30 from 237) of SL3-3 T-ALL with a Rasgrp1 CIS also contain a CIS
in Notch1(29). The statistical power of our large SL3-3 RIM screen supports the likelihood
that both pathways complement each other and synergize in T-ALL oncogenesis. Similarly,
we previously reported that oncogenic K-RasG12D expression from the endogenous locus
cooperated with Notch1 CIS in T lineage leukemogenesis (39), and 10 of 13 T-ALL arising
from retroviral-mediated Rasgrp1 overexpression carried Notch1 mutations (28). Given that
mutations in NOTCH1 are the most common oncogenic mutation in human T-ALL (31), it
will be of interest to determine the biochemical nature of RasGRP1 and Notch1 synergy in
human T-ALL. We speculate that specific sets of co-insertions might mirror the
heterogeneity observed in patients. Future methodical analyses of these RIM screens and
derived clonal T-ALL lines that include combined in silico, in vitro, and in vivo approaches
to examine signals (preferably with single-cell resolution) might eventually reveal a
blueprint of cooperating signaling networks that could help deconvolute the complexity of
hyperactive Ras signaling in human cancer.
Materials and Methods
Computational models
For Fig. 1, A and B, fig. S1, B and C, and Fig. 5, D and E, we modeled the signaling
network described in the supplemental Table SIV of Das et al.(24), as depicted in fig. S1A
with the dotted area excluded. For Fig. 6, A, B, and F, we used the model in Fig. 1A of
Riese et al.(51), which is an extended model that accounts for receptor input, as depicted in
fig. S1A with the dotted area included. We performed stochastic simulations of signaling
networks by solving the corresponding Master equation with the standard Gillespie
algorithm (71). The Master equation is a probabilistic description of the time evolution of an
intrinsically stochastic system governed by a set of coupled chemical reactions. We found
deterministic steady-state amounts of RasGTP by finding the fixed points of the ordinary
differential equations (ODEs) describing the system. In all stochastic simulations, we used a
spatially homogeneous simulation box of size V = area (4 mm2) × height (0.02 mm). This
choice of the system size ensures that the system is well-mixed. The initial concentrations
and the rate constants were those in Tables S1 to S4 of Das et al.(24) and Tables 1 to 2 of
Riese et al.(51), except that we used 36 molecules/μm for PIP2 to match their published
results (51). More details of the simulation technique and choice of parameters can be found
in the supplemental material of Das et al.(24) and Riese et al.(51).
Real-time RT-PCR
Total RNA was isolated from human bone marrow and cell lines derived from mouse
leukemias with Trizol (Invitrogen) extraction according to the manufacturer's protocol. RNA
was reverse-transcribed with random primers (Invitrogen) and M-MLV reversetranscriptase.
Real-time PCR was performed in triplicate with AmpliTaq Gold (AppliedBiosystems) and
the Applied Biosystems ABI 7300 thermocycler. The extents of geneexpression were
normalized to that of GAPDH and quantified with the comparative CTmethod according to
the manufacturer's instructions. The following combinations ofprimers and probes were used
to analyze the expression of mouse Rasgrp1: forward:TGGGCTTTCCACACAACTTTC;
reverse: CACCAGGTCTTTGCACTGTTTG; probe:FAM-
AGAAACCACTTACCTGAAGCCCACCTTCTG-TAMRA; and human RasGRP1:
forward: AAGCTCCACCAACTACAGAACT; reverse:
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CCACATGAAATCAATAAGGTTCTCGGTGAG-TAMRA. Of note, bone marrow
samples were taken from T-ALL patients at blast crisis and consisted of a typically high
percentage of blasts in the marrow (close to 100%) and these samples were therefore
relatively homogeneous.
Gene expression profiling of pediatric T-ALL patients
We used the RNeasy isolation kit (Qiagen) to isolate RNA from pre-treatment leukemic cell
suspensions obtained from peripheral blood or bone marrow. Complementary DNA (cDNA)
labeling, hybridization to U133_Plus_2 arrays (Affymetrix), and scanning were performed
at the Keck-UNM Genomics Resource. The default RMA and MAS5 algorithms of
Expression Console (Version 1.1; Affymetrix) were used to generate and normalize signal
intensities, as previously described (72-74).
T-ALL clinical trials and correlative analyses
After obtaining written informed consent in accordance with local institutional guidelines,
we collected peripheral blood and bone marrow from patients that were enrolled in the
Children's Oncology Group studies 9900/9404 and AALL03B1/AALL0434, and we
processed and cryopreserved these samples for future tissue analyses. Failure to achieve a
first remission (induction failure, IF), relapse after achieving a first remission (RE), and
complete continuous remission (CCR) were annotated for each patient. Further details
regarding study design and outcome correlates are available as previously described (74, 75)
or at http://www.cancer.gov/clinicaltrials. Analyses of robust multichip average (RMA)-
normalized data were performed with Prism 4 (Graphpad Software, Inc).
Generation and propagation of murine T-ALL cell lines
Frozen primary tumors from our previous SL3-3 screen (29) were thawed in complete RPMI
medium (Invitrogen) containing 20% fetal bovine serum (FBS), penicillin (100 U/ml),
streptomycin (100 μg/ml), 55 μM β-mercaptoethanol, and IL-2, IL-7, and IL-9 (each at 10
ng/ml), which resulted in the generation of bulk in vitro T-ALL cultures. Clonal T-ALL cell
lines were then generated by limiting dilution. All T-ALL lines were subsequently
propagated in RPMI, 10% FBS, containing penicillin, streptomycin, and β-mercaptoethanol.
The K-RasG12D T-ALL 6, 3, and 51 cell lines were grown in the same medium
supplemented with IL-2, IL-7, and IL-9 (each at 10 ng/ml).
In vitro stimulation and biochemical analyses
To analyze RasGTP abundance under basal conditions, we washed T-ALL lines with PBS
containing magnesium and calcium and rested them in PBS for 2 hours at 37° before
subjecting the cells to RasGTP pull-downs as described previously (24). For stimulations,
cells were washed and rested in PBS for 30 min and stimulated with PMA (25 ng/ml) or
with IL-2, IL-7, and IL-9 (each at 100 ng/ml), followed by RasGTP pull-downs and
preparation of NP-40 lyates. NP-40 lysis buffer was supplemented with protease and
phosphatase inhibitors (10 mM sodium fluoride, 2 mM sodium orthovanadate, 0.5 mM
EDTA, 2 mM PMSF, 1 mM sodium molybdate, 10 ug/ml aprotonin, 10 ug/ml leupeptin, 1
ug/ml pepstatin) and lysates were incubated for 20 min at 4°C. Western blotting analysis
was performed with antibodies specific for murine Rasgrp1 (m199, a gift from J. Stone), α-
tubulin (Sigma), Ras (Upstate), phosphorylated p53 at Ser (Cell Signaling), p21 (M-19,
Santa Cruz Biotechnologies), phosphorylated PLC-γ1 pY783 (Invitrogen), phosphorylated
ERK1/2 (p44/42 MAPK, Cell Signaling), phosphorylated IκBα Ser32 (Cell Signaling), and
phosphorylated Akt Ser473 (Cell Signaling). To detect human RasGRP1, we generated a
rabbit monoclonal antibody, JR-E80-2, by immunization with
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GPFTFPNGEAVEHGEESKDRTIMLM-RasGRP1 peptide together with Epitomics.
Western blots were visualized with Enhanced Chemiluminescence (ECL) and imaging on a
Fuji LAS 4000 image station (GE Healthcare). The protein bands in Western blots were
quantified with Multi Gauge software and densitometry (pixel intensity) was determined
within the linear range of the exposure. Amounts of the proteins of interest are typically
presented as a ratio of a loading control.
Measurement of in vitro proliferation of K-RasG12D and Rasgrp1 T-ALL cell lines
T-ALL cell lines were seeded at 1 × 106 cells/ml in complete RPMI medium (Invitrogen)
containing 10% FBS, penicillin, streptomycin, and β-mercaptoethanol; medium with 20% of
the normal amount of FBS; or complete RPMI medium containing doxorubicin (100 ng/ml).
Cell lines were grown with or without IL-2, IL-7, and IL-9 (each at 10 ng/ml). Samples were
collected after 24, 48, 72, and 96 hours and counted with a Vi-Cell cell viability analyzer
(Beckman Coulter).
Analysis of the p53-p21CIP cell cycle arrest pathway
4 × 106 cells were harvested from T-ALL lines from in vitro growth assays after 6 and 24
hours. Samples were also collected for staining with AnnexinV and PI (BD Biosciences) and
were processed according to the manufacturer's protocol. Cells were centrifuged,
resuspended in RIPA lysis buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 50 mM
MOPS, 150 mM sodium chloride, 2 mM EDTA) supplemented with protease and
phosphatase inhibitors. Lysates were centrifuged for 20 min at 4°C and 2× sample buffer
was added to the supernatants. Protein samples were separated on a pre-cast 4-12% gradient
gel (Invitrogen) for P-p53 and p21 analysis.
In vivo proliferation of K-RasG12D and Rasgrp1 T-ALL lines
1 × 105-ALL cells were injected subcutaneously into Nude-Foxn1nu mice (Harlan). Tumor
volume was determined by external caliper: tumor volume = ½ (length × width2). Mice were
monitored and euthanized once adverse effects were observed. Tumors were removed and
single-cell suspensions were prepared for protein and RNA extraction. Cells were
resuspended in NP-40 lysis buffer supplemented with protease and phosphatase inhibitors
and incubated at 4°C for 20 min. Lysates were centrifuged at 4°C for 20 min, and sample
buffer was added to the supernatants. Proteins were separated on a 10% SDS-
polyacrylamide gel and were analyzed by Western blotting. Mice were handled according to
IACUC regulations, described in the Roose lab's UCSF mouse protocol AN084051 “Ras
Signal Transduction in Lymphocytes and Cancer”.
shRNA experiments
Oligonucleotides containing HapI and XhoI sites were annealed and ligated into Hap1-and
XhoI-digested pSicoR-puro-t2a-eGFP (http://viracore.ucsf.edu/vectordb) to
createmRasgrp1-1503- pSicoR-puro-t2a-eGFP and hRasGRP1-1503- pSicoR-puro-t2a-
eGFP.Oligonucleotide sequences are as follows. For mRasgrp1-1503: Sense
oligonucleotide: 5′-
TGATCGCTGCAAGCTTTCCATTCAAGAGATGGAAAGCTTGCAGCGATCTTTTTTC
-3′; Antisense oligonucleotide: 5′-
TCGAGAAAAAAGATCGCTGCAAGCTTTCCATCTCTTGAATGGAAAGCTTGCAGC
GATCA-3″. For hRasGRP1-1503: Sense oligonucleotide: 5′-
TGATTGCTGCGAGTTTTCCATTCAAGAGATGGAAAACTCGCAGCAATCTTTTTTC
-3′; Antisense oligonucleotide: 5′-
TCGAGAAAAAAGATTGCTGCGAGTTTTCCATCTCTTGAATGGAAAACTCGCA
GCAATCA-3′. Targeting of the 1503 region was based on previous work (76).
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hRasGRP1-1503 targets human RasGRP1, has three mismatches with the same sequence in
mRasgrp1-1503, and served as a specificity control. Clonal T-ALL lines were infected with
lentivirus through standard spin-infections and selected by culture in the presence of
puromycin (0.5 μg/ml). Similarly, annealed oligonucleotides were ligated into pSicoR-puro-
t2a-eGFP to create mSos1-1313- pSicoR-puro-t2a-eGFP and hSOS1-1313- pSicoR-puro-
t2a-eGFP, based on published targeting sequences (77). hSOS1-1313 targets humanSOS1,
has two mismatches with the same sequence in mSos1-1313, and serves as aspecificity
control. For mSos1-1313: Sense oligonucleotide: 5′-
TGACAGTGTTGCAATGAGTTTTCAAGAGAAACTCATTGCAACACTGTCTTTTTTC
-3′, Antisense oligonucleotide: 5′-
TCGAGAAAAAAGACAGTGTTGCAATGAGTTTCTCTTGAAAACTCATTGCAACAC
TGTCA-3′; For hSOS1-1313: Sense oligonucleotide: 5′-
TGACAGTGTTGTAATGAATTTTCAAGAGAAATTCATTACAACACTGTCTTTTTTC-
3′, Antisense oligonucleotide: 5′-
TCGAGAAAAAAGACAGTGTTGTAATGAATTTCTCTTGAAAATTCATTACAAC
ACTGTCA-3′.
In vivo comparison of Rasgrp1 T-ALL cells and Rasgrp1 T-ALL cells containing Rasgrp1-
specific shRNA
Balb/C mice (Harlan) were injected with 4 × 103 Rasgrp1 or shRNA Rasgrp1 T-ALL cells
by retro-orbital injection. Mice were euthanized after 14 days, and lymph nodes, spleen,
liver, thymus, lungs, kidneys, and femurs were removed. Single-cell suspensions were
prepared and analyzed to determine the percentage of GFP+ cells present in each tissue by
flow cytometry. Unpaired student t tests were applied to explore the effects of Rasgrp1
knockdown.
Sternums and livers were fixed in 10% buffer formalin (Fisher Scientific) for 24 hours and
maintained in 70% ethanol at 4°C until they were embedded in paraffin. 10-μm paraffin-
embedded sections were stained with H&E or with anti-Rasgrp1 antibody (AbCam 37927)
to detect Rasgrp1 abundance, and slides were used for descriptive histopathology. Briefly,
slides were deparaffinized and rehydrated followed by antigen retrieval in Trilogy buffer
(Cell Marque) at 90°C for 45 min. Slides were washed in PBS-T (0.1% Tween 20 in PBS),
blocked with blocking buffer [50 mM Tris-HCl (pH 7.6) containing 1% BSA], and stained
with primary antibody (rabbit anti-RasGRP1 antibody at a 1:500 dilution) overnight at 4°C.
After washing with PBS-T, slides were incubated with Alexa Fluor 488–conjugated donkey
anti-rabbit antibody (Invitrogen, 1:1000) for 50 min at room temperature. Slides were
washed and mounted with Vectashield mounting medium (Vector Laboratories).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Increased RasGRP1 abundance is a common feature of human T-ALL. (A and B) In silico
prediction of the effect of changing (A) the catalytic rates and (B) the concentrations of
RasGAP and RasGRP1 on Ras activation. The SOS concentration was set at a basal amount
(5 simulation concentration units) here. Each data point reported represents the average of
10,000 simulation trajectories at 200 simulation time units. The error bars indicate standard
deviations, which measure cell-to-cell variability. Qualitatively similar results were
observed when the SOS concentration was increased from 5 to 15 (see figs. S1, B and C).
(C) Western blotting analysis of RasGRP1 protein abundance in a panel of established
human T-ALL lines with abundance in normal T cells arbitrarily set at 1. Data are a
representative example of three independent experiments. (D) Real-time RT-PCR analysis
of RasGRP1 expression in bone marrow samples of pediatric T-ALL patients (T, 18 years or
younger) or healthy donors (N). RasGRP1 mRNA abundances were normalized to those of
GAPDH, and RasGRP1 expression was arbitrarily set to 1.0 in the sample from healthy
donor N-1. (E and F) Standard Affymetrix analyses were used to generate and normalize
signal intensities of RasGRP1 mRNA abundances in samples from 107 pediatric patients
enrolled in Children's Oncology Group studies 9900/9404 and AALL03B1/AALL0434.
Analyses of RMA-normalized data were plotted and indicated a statistically significant 128-
fold range in the abundance of RasGRP1 mRNA, but not of any other RasGEF mRNA.
(G)RasGRP1 mRNA abundance plotted as a function of clinical outcome. Low RasGRP1
mRNA abundance correlated with IF. Patients with greater RasGRP1 mRNA abundance in
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general went into remission followed by relapse (RE) or displayed complete continuous
remission (CCR).
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Retroviral insertions in the Rasgrp1 locus are frequent in mouse T-ALL and result in
enhanced Rasgrp1 expression, whereas CIS in the genes encoding other RasGEFs or
RasGAPS are rare. (A) Overview of the four most frequent insertion sites as determined by
our in vivo BalbC mouse screen. Fathers of mice injected with SL3-3 were mutagenized by
ENU. (B) Frequency of SL3-3 CIS in the other seven RasGEF-encoding genes. (C)
Numbers of SL3-3 insertions in seventeen RasGAP-encoding genes. (D) Genomic locations
of SL3-3 insertions in Rasgrp1. See figs. S2 and S3A for a detailed map of the insertions in
Rasgrp1. (E) Increased Rasgrp1 mRNA abundance in clonal SL3-3 lymphoma cell lines that
were generated from the primary tumor 3397S, which had an SL3-3 insertion in the Rasgrp1
promoter, as well as from tumors 1713S and 1156S, which had insertions in intron 1. The
abundances of Rasgrp1 mRNA in these lines were compared to that in the control T-ALL 98
cell line in which Rasgrp1 mRNA abundance, as determined by real-time RT-PCR, was
arbitrarily set at 1.0. Data are means and standard errors from three independent
experiments.
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Rasgrp1 and K-RasG12D oncogenes induce Ras activation to different extents and drive
proliferation in distinct manners. (A) Analysis of basal RasGTP and Rasgrp1 abundances in
the indicated Rasgrp1 and K-RasG12D T-ALL lines. Only 20% of the RasGTP pull-down
material was loaded for all K-RasG12D lines to remain in the dynamic range for
quantification by Western blotting analysis, which was later corrected by a factor of five.
The abundance of RasGTP in 1156S-O cells was arbitrarily set to 1.0 by normalizing to the
abundance of α-tubulin protein. (B) Analysis of the p53-P21CIP cell cycle arrest pathway in
the indicated T-ALL lines. Phosphorylated p53 (pp53) was measured 6 hours after seeding
the cells in culture medium, whereas p21 abundance was determined after 24 hours. Protein
loading controls and positive controls for cell cycle arrest triggered by doxorubicin are
presented in fig. S4. (C) In vitro proliferation assays were performed with cells incubated
over a 100-hour time period with complete medium (condition 1, brown), medium with 20%
of normal serum content (condition 2, orange), or complete medium with doxorubicin
(condition 3, blue). Cells were seeded at 106/ml, and live cells were counted over the time
period. A combination of IL-2, IL-7, and IL-9 was added to the culture medium to ensure
sufficient growth factor presence. For additional growth curves and measurement of
proliferation in the absence of cytokines, see figs. S4 and S5. Data in (A) to (C) are
representative of three or more experiments. (D) Analysis of the in vivo proliferative
potential of K-RasG12D and Rasgrp1 T-ALL cells. 1 × 105 T-ALL cells were injected
subcutaneously into nude mice and proliferation was determined by measuring tumor
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volume (in cm3) over time. For additional images and growth curves see fig. S6. Each curve
is derived from a single mouse.
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Potential role of cytokine signaling in Rasgrp1 T-ALL. (A and B) We used realtime RT-
PCR analysis to measure the abundances of IL2, IL7, and IL9 mRNAs in the indicated T-
ALL cell lines that were maintained in an exponential log phase in tissue culture in complete
medium. In (B), CD4+ T cells that were activated with PMA and ionomycin were used as a
positive control for IL9 expression. Relative mRNA abundances are plotted as the Log2 of
the inverse function of the ΔCT (difference in cycles), normalized to the abundance of
GAPDH mRNA. Data are means and standard errors from three independent experiments.
(C) Real-time RT-PCR analysis of cytokine mRNAs from T-ALL that proliferated
subcutaneously in nude mice. Means (horizontal bars) and abundances in individual tumors
(symbols) are plotted. (D) Quantification of the frequency of GFP-containing (GFP+) T-
ALL cells in individual mouse organs as determined by flow cytometric analysis. Five mice
of each group were injected with 4,000 T-ALL cells and were analyzed 14 days later. See
fig. S7 for results with the 3397 T-ALL cell line. Data are representative of two independent
experiments, and each dot represents an individual mouse. Note the statistically significantly
reduction in GFP+ cells in the bone marrow and liver when Rasgrp1 was knocked down with
shRNA (P < 0.05. (E and F) Histological analysis of T-ALL. (E) H&E staining of blood
smears at 17 days after subcutaneous injection for GFP-labeled 1156S-O-GFP T-ALL
demonstrated a high frequency of T-ALL cells circulating in the blood (blue cells). Injection
of 20,000 cells for 1156S-O-shRNA Rasgrp1 cells resulted in fewer T-ALL in the blood,
monitored at 22 days after injection. (F) Analysis of bone marrow and liver sections from
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the mice in (D) with H&E and Rasgrp1-staining. The morphology of the bone marrow and
liver as well as the presence of T-ALL blasts and Rasgrp1 abundance were analyzed by
sections and H&E and Rasgrp1 staining. Representative images are shown from three mice
for each condition tested.
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DAG has the potential to activate Rasgrp1 and stimulate increased RasGTP production in T-
ALL. (A to C) PMA induced rapid and enhanced Ras activation in a Rasgrp1-dependent
manner. RasGTP pull-down assays and analysis of Rasgrp1 abundance in the indicated T-
ALL cell lines that were serum-starved and then stimulated with PMA (25 ng/ml) for the
indicated times. The amount of RasGTP in resting 1156S-O T-ALL was arbitrarily set at
1.0. For downstream ERK activation patterns, see fig. S8. Data in (A) to (C) are
representative of three or more experiments. (D and E) The deterministic steady-state
amount of RasGTP modeled as a function of DAG and Rasgrp concentrations at different
low amounts of Sos. The amounts of Sos were arbitrarily set at 5 and 15 activation units.
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The abundance of Rasgrp1, but not Sos1, is important for cytokine-induced Ras activation in
T-ALL. (A and B) RasGTP production as a function of Rasgrp concentration and receptor
input at (A) t = 5 simulation time units and (B) t = 15 simulation time units. Each data point
represents the average of 10,000 simulation trajectories. (C to E) Cytokine stimulation
induces strong, but transient, Ras activation in the Rasgrp1 1156S-O and C6 T-ALL cell
lines and enhanced production of RasGTP in the K-RasG12D T-ALL 3 cell line. Lentivirally
expressed shRNA led to Rasgrp1 knockdown in 1156S-O and T-ALL C6 by 55 and 38%,
respectively, which resulted in decreases in cytokine-induced RasGTP abundance. Note that
Sos1 abundance was unchanged. (F) Computational predictions of receptor-induced Ras
activation as described in (A) and (B) but in which all input from SOS has been removed.
(G) In contrast to the substantial decrease in cytokine-induced Ras activation in T-ALL C6
after a 38% reduction in Rasgrp1 abundance, a reduction in Sos1 abundance by 42% in the
same C6 T-ALL cell line had no substantial effect on RasGTP generation. As a specificity
control for the shRNA for murine Sos1, C6 T-ALL cells were transduced with lentivirus
expressing shRNA specific for human SOS1. Data in (C) to (E) and in (G) are representative
of three independent experiments. (H) Patterns of phosphorylation of ERK, Akt, and IκBα
in unstimulated human T-ALL lines. Data are representative of two experiments. (I)
Pathway analysis of individual subcutaneous T-ALL tumors (from experiments in Fig. 3D
and fig. S6). The patterns of phosphorylation of ERK, Akt, and IκB demonstrate complex
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heterogeneity in K-RasG12D T-ALL as well as plasticity in Rasgrp1 T-ALL. Data are
representative of three experiments.
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